The FDA approved Moderna's lower-dose Covid-19 vaccine, mNEXSPIKE, for adults 65+ and those 12-64 with underlying health conditions who have previously received a Covid vaccine. Available for the 2025-26 respiratory virus season, it offers a lower-dose alternative, not a replacement. This approval follows a recent FDA decision to limit approvals to these groups and aligns with the Trump administration's stricter vaccine eligibility guidelines. The vaccine demonstrated higher antibody levels and fewer side effects compared to Moderna's original shot in clinical trials.

Prepared by Olivia Bennett and reviewed by editorial team.